Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells

被引:151
|
作者
Zhao, Yunlong [1 ]
Harrison, Devin L. [2 ]
Song, Yuran [1 ]
Ji, Jie [2 ,3 ]
Huang, Jun [2 ]
Hui, Enfu [1 ]
机构
[1] Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA
[2] Univ Chicago, Inst Mol Engn, Chicago, IL 60637 USA
[3] Nanjing Med Univ, Clin Med Coll 1, Dept Hepatobiliary Surg, Nanjing 210029, Jiangsu, Peoples R China
来源
CELL REPORTS | 2018年 / 24卷 / 02期
基金
美国国家科学基金会;
关键词
COSTIMULATORY RECEPTOR; CANCER-IMMUNOTHERAPY; B7; FAMILY; EXPRESSION; ACTIVATION; EXHAUSTION; SECRETION; BIOMARKER; BILAYERS; SURVIVAL;
D O I
10.1016/j.celrep.2018.06.054
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (PD-L1) on antigen- presenting cells (APCs), is a major mechanism of tumor immune evasion. PD-1 and PD-L1 blockade antibodies have produced remarkable clinical activities against a subset of cancers. Binding between T cell-intrinsic PD-1 and APC-intrinsic PD-L1 triggers inhibitory signaling to attenuate the T cell response. Here, we report that PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating APCs. Using reconstitution and cell culture assays, we demonstrate that the co-expressed PD-1 binds to PD-L1 in cis. Such interaction inhibits the ability of PD-L1 to bind T cell-intrinsic PD-1 in trans and, in turn, represses canonical PD-L1/PD-1 inhibitory signaling. Selective blockade of tumor-intrinsic PD-1 frees up tumor-intrinsic PD-L1 to inhibit T cell signaling and cytotoxicity. Our study uncovers another dimension of PD-1 regulation, with important therapeutic implications.
引用
收藏
页码:379 / +
页数:18
相关论文
共 50 条
  • [31] PD-1/PD-L1 as a prognostic factor in leukemia
    Hadi Rezaeeyan
    Seyedeh Nafiseh Hassani
    Mojgan Barati
    Mohammad Shahjahani
    Najmaldin Saki
    Journal of Hematopathology, 2017, 10 : 17 - 24
  • [32] PD-1/PD-L1 Axis in Lung Cancer
    Santini, Fernando C.
    Hellmann, Matthew D.
    CANCER JOURNAL, 2018, 24 (01): : 15 - 19
  • [33] Expression of PD-L1 and PD-1 in Cutaneous Warts
    Yu, Wesley
    Berger, Timothy
    Laszik, G. Zoltan
    North, Jeffrey
    Cohen, Jarish
    LABORATORY INVESTIGATION, 2019, 99
  • [34] The PD-1:PD-L1 axis in Inflammatory Arthritis
    Mary Canavan
    Achilleas Floudas
    Douglas J. Veale
    Ursula Fearon
    BMC Rheumatology, 5
  • [35] Regulatory mechanisms of PD-1/PD-L1 in cancers
    Lin, Xin
    Kang, Kuan
    Chen, Pan
    Zeng, Zhaoyang
    Li, Guiyuan
    Xiong, Wei
    Yi, Mei
    Xiang, Bo
    MOLECULAR CANCER, 2024, 23 (01)
  • [36] Toxicities Associated With PD-1/PD-L1 Blockade
    Wang, Daniel Y.
    Johnson, Douglas B.
    Davis, Elizabeth J.
    CANCER JOURNAL, 2018, 24 (01): : 36 - 40
  • [37] Biomarkers of response to PD-1/PD-L1 inhibition
    Vareki, Saman Maleki
    Garrigos, Carmen
    Duran, Ignacio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124
  • [38] PD-1 and PD-L1 blockade in gastrointestinal malignancies
    Lote, Hazel
    Cafferkey, Catherine
    Chau, Ian
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 893 - 903
  • [39] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [40] Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Nowicki, Theodore S.
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    CANCER JOURNAL, 2018, 24 (01): : 47 - 53